Videos | Page 5

Effect-of-Beta-Blockers-on-Mortality-after-Myocardial-Infarction-in-Adults-with-COPD
Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.
Marine-Compound-Discovery-Shows-Promise-of-Improved-Drug-Treatment-for-COPD-Patients
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
COPD-Research
Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar “COPD—Bridging the Gap between Science and Clinical Care.”
Keeping-Pace-with-Racing-Hearts-Get-With-the-GuidelinesAFIB
An overview of “Get with the Guidelines – AFIB,” a quality-improvement program created by the American Heart Association for health care providers.
New-Anticoagulants-for-Stroke-Prevention-in-Atrial-Fibrillation
Christian Ruff, MD, MPH, gives an overview of the anticoagulants currently available for prevention of stroke in patients with atrial fibrillation.
Atrial-Fibrillation-Research
Chris Cannon, MD, FACC, discusses 3 research papers on atrial fibrillation in this video produced by the American College of Cardiology.
Potential-for-Abuse-of-Hydrocodone-Combination-Products
Mary Lynn McPherson, PharmD, discusses the appeal of hydrocodone combination products to drug abusers.
Evidence-for-Rescheduling-Hydrocodone-Combination-Products
Jeff Fudin, PharmD, FCCP, argues that there is no evidence to support categorizing hydrocodone combination products as Schedule II drugs rather than Schedule III drugs.
Increased-Opioid-Usage
In the first in a series of videos on regulation of hydrocodone combination products, Mary Lynn McPherson, PharmD, discusses the dramatic increase in the use of opioids in the United States.
Fourth-Generation-Pharmacist
Fourth-generation pharmacist Joe Moose, PharmD, reflects on how pharmacy practice has changed and remained the same over the years.
$AD300x250BB$
Latest Issues
$auto_registration$